In more validation that ADCs will continue to be an important new drug class for fighting cancers as we move forward, Piramal announced that it will be building a new facility for their manufacture in Scotland. The investment is $2.5 M for the expanded digs to increase their capacity.
Piramal says the addition is needed as they have more customers moving into phase II and phase III clinicals with these products and they need to be able to operate at higher scale to support commercialization. Piramal will also add to its proof-of-concept offer at the site to enable companies to demonstrate antibody and/or toxin suitability for use as an ADC. Piramal says this investment is just phase I of a two to three phase expansion that can be expected over the next 5 years. What is it waiting for? See In-pharma Technologist.
Posted by Bruce Lehr Aug 5th 2013.